“So, I'd say it's more near-term. The next couple of -- maybe, I don't know if it will exactly happen in the fiscal year, but we're in that ballpark and really excited about it.”

In context

“e really happy with that. And then you've got a nice robust demand, a robust pipeline. Like I said in the commentary, the only thing that's more exciting than a Sphere-9 catheter out there right now is the Sphere-360 and that goes right at the heart of the competition, right at them. And then we've got PulseSelect which is not under any kind of supply constraints. And it gives centers around the world an option and a way to blend the pricing as well. So especially in the global areas where the resources aren't as much, you got PulseSelect, a very good system, high quality, very safe, and it's not priced where the Affera is. And so what I would say is that we strongly believe in doubling the business. We didn't put a specific timeframe on it, but it's not far off. I mean, it's not far off. So, I'd say it's more near-term. The next couple of -- maybe, I don't know if it will exactly happen in the fiscal year, but we're in that ballpark and really excited about it. Danielle Antalffy: That's so helpful. Thanks so much. Ryan Weispfenning: Thank you, Danielle. Let's take the last question, please, Wynne. Operator: Our last question comes from Shagun Singh at RBC. Shagun Singh: Great. Thank you so much. So, a couple of follow-ups on the CAS business. Impressive growth. Can you talk about the mix of cryo? It seems like it's becoming less and less of a headwind. Any color on pricing there? And then on RDN, any updated thoughts on what patient subset you think you could get coverage for? Thank you for taking the questions. Geoff Martha: Sean, do you want to take the first one? Sean Salmon: Sure, thanks, Shagun. Yes, so first of all, on CAS, cryo will become less and less part of the mix, but I think that rate of decline will slow and then that will really”